The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update

Mehra, Mandeep R.; Canter, Charles E.; Hannan, Margaret M.; Semigran, Marc J.; Uber, Patricia A.; Baran, David A.; Danziger‐Isakov, Lara; Kirklin, James K.; Kirk, Richard; Kushwaha, Sudhir S.; Lund, Lars H.; Potena, Luciano; Ross, Heather J.; Taylor, David O.; Verschuuren, Erik; Zuckermann, Andreas

doi:10.1016/j.healun.2015.10.023

Cited by 1,221 publications

(1,027 citation statements)

References 140 publications

Supporting

Mentioning

936

Contrasting

Unclassified

Order By: Relevance

“…odrzucanie zależne od przeciwciał, zakażenia, nadciśnienie tętnicze, niewydolność nerek, nowotwory, waskulopatia tętnic wieńcowych). Niedawno dokonano aktualizacji wskazań i przeciwwskazań do przeszczepienia serca, które podsumowano w tabeli 13.4 [616]. Należy pmiętać, że część z przeciwwskazań ma charakter przemijający i może podlegać leczeniu.…”

Section: Terapia Docelowa (Dt)unclassified

“…Podczas gdy czynne zakażenie pozostaje względnym przeciwwskazaniem do przeszczepienia serca, pacjenci z HIV, wirusowym zapaleniem wątroby, chorobą Chagasa i gruźlicą mogą być rozważani jako potencjalni kandydaci do przeszczepienia pod warunkiem, że zajmujący się nimi specjaliści będą przestrzegać ścisłych zaleceń dotyczących poszczególnych terapii. U osób wymagających przeszczepienia serca, ze współwystępującą chorobą nowotworową należy w każdym przypadku precyzyjnie określić ryzyko nawrotu choroby w ścisłej współpracy ze specjalistami w dziedzinie onkologii [616].…”

Section: Terapia Docelowa (Dt)unclassified

See 1 more Smart Citation

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

459

446

View full text Add to dashboard Cite

Section: Terapia Docelowa (Dt)unclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

459

446

View full text Add to dashboard Cite

“…Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) are two of the most widely utilized scores. Both models have their own intrinsic limitations but both have been shown to give fairly reasonable estimates of 1-year survival and have been recommended as consideration for HTx selection (49).…”

Section: Clinical Risk Prediction and Comparative Survival Benefit Ratimentioning

confidence: 99%

Current indications for transplantation: stratification of severe heart failure and shared decision-making

Vucicevic¹,

Honoris²,

Raia³

et al. 2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

Heart failure (HF) is a complex clinical syndrome that results from structural or functional cardiovascular disorders causing a mismatch between demand and supply of oxygenated blood and consecutive failure of the body's organs. For those patients with stage D HF, advanced therapies, such as mechanical circulatory support (MCS) or heart transplantation (HTx), are potentially life-saving options. The role of risk stratification of patients with stage D HF in a value-based healthcare framework is to predict which subset might benefit from advanced HF (AdHF) therapies, to improve outcomes related to the individual patient including mortality, morbidity and patient experience as well as to optimize health care delivery system outcomes such as costeffectiveness. Risk stratification and subsequent outcome prediction as well as therapeutic recommendationmaking need to be based on the comparative survival benefit rationale. A robust model needs to (I) have the power to discriminate (i.e., to correctly risk stratify patients); (II) calibrate (i.e., to show agreement between the predicted and observed risk); (III) to be applicable to the general population; and (IV) provide good external validation. The Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score (HFSS) are two of the most widely utilized scores. However, outcomes for patients with HF are highly variable which make clinical predictions challenging. Despite our clinical expertise and current prediction tools, the best short-and long-term survival for the individual patient, particularly the sickest patient, is not easy to identify because among the most severely ill, elderly and frail patients, most preoperative prediction tools have the tendency to be imprecise in estimating risk. They should be used as a guide in a clinical encounter grounded in a culture of shared decision-making, with the expert healthcare professional team as consultants and the patient as an empowered decision-maker in a trustful safe therapeutic relationship.

show abstract

“…The second group consists of patients with myocardial infarction, acute myocarditis or end-stage heart disease who are not expected to recover adequate cardiac function and who require mechanical support as a bridge to transplantation (3). Currently developed VADs include extracorporeal membrane oxygenation, ventricular and biventricular extracorporeal and implantable continuous and pulsatile devices, and total artificial hearts (7).…”

Section: Ventricular Assist Devicesmentioning

confidence: 99%

Cardiac Compression Devices: Alternative Technology and Innovative Concept

Daliri

Yadollahi

Jadbabaei

2017

Multidiscip Cardio Annal

View full text Add to dashboard Cite

Heart failure is a leading cause of death around the world. Heart transplantation is the only reliable therapy for improving functional capacity, quality of life, life expectancy, and limiting the options for heart failure patients. In fact, a large number of patients with severe heart failure in need of heart transplantation are unable to receive therapy with up to 30% mortality before a heart is donated. In recent decades, cardiac replacement and assisting therapies have presented promising outcomes to treat these end-stage patients as alternative solutions. These devices are capable of providing temporary to permanent, partial or full assistance. Such devices can be divided into two categories based on location and mechanism of augmentation: 1) devices exposed directly to blood including ventricular assistive devices (VADs) and total artificial hearts (TAHs) and 2) devices that augment cardiac output through compression of ventricles or another part of circulatory system with no direct contact to blood such as extra-cardiac compression devices (ECCDs). In recent years, novel ECCDs which compress tissue and muscles to indirectly assist blood pumping have been developed to circumscribe problems associated with blood-contacting devices and the risks involved with piercing arterial and ventricular walls. Not only do ECCDs aim to reduce risks from the patient and surgeon perspective, the complexity of engineering an intra-corporeal extra-cardiac device is also reduced.

show abstract

The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update

Cited by 1,221 publications

References 140 publications

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Current indications for transplantation: stratification of severe heart failure and shared decision-making

Cardiac Compression Devices: Alternative Technology and Innovative Concept

Contact Info

Product

Resources

About